Spotlight on Internal Medicine

Credits: 0.25 CME / MOC
Alzheimer’s Disease: Early Identification and Future Therapeutic Landscape—The Critical Importance of Early Diagnosis of Alzheimer’s Disease With Drs. Raymond Scott Turner and Sharon Cohen
Raymond Scott Turner, PhD, MD, FAAN, FANA
Vindico

Alzheimer’s Disease: Early Identification and Future Therapeutic Landscape—The Critical Importance of Early Diagnosis of Alzheimer’s Disease With Drs. Raymond Scott Turner and Sharon Cohen

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/ ABIM MOC
Released: December 31, 2020
Expires: December 30, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, primary care physicians, and other health care professionals involved in the management of patients with Alzheimer’s disease.

Learning Objective

Upon successful completion of the activity, participants should be better able to review the critical importance of diagnosing patients in the early stages of AD including the latest evidence-based diagnostic strategies and modalities.

Activity Description

Alzheimer’s disease (AD) is an irreversible, age-related neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living. More than 5 million Americans are living with AD, which accounts for 60% to 80% of all dementia. By 2050, the number of Americans living with AD is projected to rise to 14 million. Despite this significant burden, currently approved AD treatments are symptomatic drugs that do not stop or delay disease progression, with no approved disease-modifying therapy. The latest data from emerging AD treatments suggest that early identification of AD patients is critical for optimizing outcomes. Thus, neurologists, primary care physicians, and other providers who care for these patients need education on strategies for the early identification and management of patients with AD. In this podcast, expert clinicians will discuss why it is important to diagnose Alzheimer’s disease early and available assessment tools to make an early diagnosis.

Activity Chair

Raymond Scott Turner, PhD, MD, FAAN, FANA
Professor of Neurology
Georgetown University
Washington, DC

Disclosure:
Consulting Fee: Re:Cognition


Faculty

Sharon Cohen, MD, FRCPC
Medical Director and Principal Investigator, Toronto Memory Program
Toronto, Canada

Disclosure:
Consulting Fee: Alnylam, Biogen, Cogstate, ProMIS Neurosciences, RetiSpec
Contracted Research: AbbVie, AgeneBio, Alector, Anavex, Biogen, CCHI, Eisai, Genentech, Janssen, Lilly, RetiSpec, Roche, Vielight


Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, listen to the podcast, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)™/ ABIM MOC
Released: December 31, 2020
Expires: December 30, 2021
15 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is neurologists, primary care physicians, and other health care professionals involved in the management of patients with Alzheimer’s disease.

Learning Objective

Upon successful completion of the activity, participants should be better able to review the critical importance of diagnosing patients in the early stages of AD including the latest evidence-based diagnostic strategies and modalities.

Activity Description

Alzheimer’s disease (AD) is an irreversible, age-related neurodegenerative disorder characterized by gradual decline in understanding, memory, and ability to perform activities of daily living. More than 5 million Americans are living with AD, which accounts for 60% to 80% of all dementia. By 2050, the number of Americans living with AD is projected to rise to 14 million. Despite this significant burden, currently approved AD treatments are symptomatic drugs that do not stop or delay disease progression, with no approved disease-modifying therapy. The latest data from emerging AD treatments suggest that early identification of AD patients is critical for optimizing outcomes. Thus, neurologists, primary care physicians, and other providers who care for these patients need education on strategies for the early identification and management of patients with AD. In this podcast, expert clinicians will discuss why it is important to diagnose Alzheimer’s disease early and available assessment tools to make an early diagnosis.

Activity Chair

Raymond Scott Turner, PhD, MD, FAAN, FANA
Professor of Neurology
Georgetown University
Washington, DC

Disclosure:
Consulting Fee: Re:Cognition


Faculty

Sharon Cohen, MD, FRCPC
Medical Director and Principal Investigator, Toronto Memory Program
Toronto, Canada

Disclosure:
Consulting Fee: Alnylam, Biogen, Cogstate, ProMIS Neurosciences, RetiSpec
Contracted Research: AbbVie, AgeneBio, Alector, Anavex, Biogen, CCHI, Eisai, Genentech, Janssen, Lilly, RetiSpec, Roche, Vielight


Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, listen to the podcast, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Biogen.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Internal Medicine Presentations

0.25 CME
Vindico
Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - State of the Art Management of Crohn’s Disease

Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - State of the Art Management of Crohn’s Disease

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
15 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty

Gary R. Lichtenstein, MD
Professor of Medicine
Raymond and Ruth Perelman School of Medicine
Director, Center for Inflammatory Bowel Disease
Department of Medicine
Division of Gastroenterology
University of Pennsylvania and University of Pennsylvania Health System
Philadelphia, PA
  • Disclosures:
  • Royalty: SLACK Incorporated
  • Consulting Fee: AbbVie, Celgene, Cellcuetix, Endo Pharmaceuticals, Ferring, Gilead, Janssen, Lilly, Luitpold/American Regent, Merck, Morphic Therapeutic, Pfizer, Prometheus, Romark, Salix/Valeant, Shire, Takeda, UCB
  • Contracted Research: Celgene, Janssen, Salix/Valeant, Shire, UCB
  • Consulting Fee (paid to institution): Janssen, Pfizer, Takeda
  • Data and Safety Monitoring Board: Lilly
  • Author Honoraria: McMahon Publishing, UpToDate
  • Editor Honoraria: American College of Gastroenterology, Clinical Advances in Gastroenterology, Gastro-Hep Communications, Springer Science and Business Media


Activity Co-chairs

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to assess the clinical safety and efficacy of available and emerging treatments for IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
15 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty

Gary R. Lichtenstein, MD
Professor of Medicine
Raymond and Ruth Perelman School of Medicine
Director, Center for Inflammatory Bowel Disease
Department of Medicine
Division of Gastroenterology
University of Pennsylvania and University of Pennsylvania Health System
Philadelphia, PA
  • Disclosures:
  • Royalty: SLACK Incorporated
  • Consulting Fee: AbbVie, Celgene, Cellcuetix, Endo Pharmaceuticals, Ferring, Gilead, Janssen, Lilly, Luitpold/American Regent, Merck, Morphic Therapeutic, Pfizer, Prometheus, Romark, Salix/Valeant, Shire, Takeda, UCB
  • Contracted Research: Celgene, Janssen, Salix/Valeant, Shire, UCB
  • Consulting Fee (paid to institution): Janssen, Pfizer, Takeda
  • Data and Safety Monitoring Board: Lilly
  • Author Honoraria: McMahon Publishing, UpToDate
  • Editor Honoraria: American College of Gastroenterology, Clinical Advances in Gastroenterology, Gastro-Hep Communications, Springer Science and Business Media


Activity Co-chairs

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to assess the clinical safety and efficacy of available and emerging treatments for IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.50 CME
Vindico
Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - State of the Art Management of Ulcerative Colitis

Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - State of the Art Management of Ulcerative Colitis

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
30 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty

Millie D. Long, MD, MPH
Associate Professor of Medicine
Director, Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
University of North Carolina at Chapel Hill
Division of Gastroenterology and Hepatology
Chapel Hill, NC
  • Disclosures:
  • Consulting Fee: AbbVie, Janssen, Pfizer, Prometheus, Salix, Takeda, Target PharmaSolutions, UCB, Valeant
  • Speakers Bureau: AbbVie, UCB
  • Contracted Research: Pfizer, Takeda


Activity Co-chairs

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to assess the clinical safety and efficacy of available and emerging treatments for IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
30 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty

Millie D. Long, MD, MPH
Associate Professor of Medicine
Director, Gastroenterology and Hepatology Fellowship Program
Vice-Chief for Education
University of North Carolina at Chapel Hill
Division of Gastroenterology and Hepatology
Chapel Hill, NC
  • Disclosures:
  • Consulting Fee: AbbVie, Janssen, Pfizer, Prometheus, Salix, Takeda, Target PharmaSolutions, UCB, Valeant
  • Speakers Bureau: AbbVie, UCB
  • Contracted Research: Pfizer, Takeda


Activity Co-chairs

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to assess the clinical safety and efficacy of available and emerging treatments for IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.50 CME
Vindico
Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - Utilizing Therapeutic Drug Monitoring

Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - Utilizing Therapeutic Drug Monitoring

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
30 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty Member and Activity Co-chair

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Activity Co-chair

Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to assess the clinical safety and efficacy of available and emerging treatments for IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
30 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty Member and Activity Co-chair

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Activity Co-chair

Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to assess the clinical safety and efficacy of available and emerging treatments for IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.50 CME
Vindico
Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - Goals of Management of IBD

Best of IBD Summit: Establishing a Foundation to Improve the Quality of IBD Care - Goals of Management of IBD

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
30 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty

Jonathan A. Leighton, MD, FACG, AGAF, FASGE, FACP
Professor of Medicine, Division of Gastroenterology and Hepatology
Vice Chair, Department of Medicine
Mayo Clinic Arizona
Phoenix, AZ
  • Disclosures:
  • Consulting Fee: Olympus
  • Contracted Research: Pfizer, Theravance Biopharma
  • Advisory Board: Check-Cap


Activity Co-chairs

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the importance of adherence to established quality measures for IBD management for both providers and patients.
  • Evaluate the components of effective treat-to-target approach for patients with IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: January 29, 2020
Expires: January 28, 2021
30 minutes to complete

Provider Statement

This continuing medical education activity is provided by

Support Statement

This activity is supported by educational grants from AbbVie, Inc.; Pfizer, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Faculty

Jonathan A. Leighton, MD, FACG, AGAF, FASGE, FACP
Professor of Medicine, Division of Gastroenterology and Hepatology
Vice Chair, Department of Medicine
Mayo Clinic Arizona
Phoenix, AZ
  • Disclosures:
  • Consulting Fee: Olympus
  • Contracted Research: Pfizer, Theravance Biopharma
  • Advisory Board: Check-Cap


Activity Co-chairs

David T. Rubin, MD, FACG, AGAF, FACP, FASGE
Joseph B. Kirsner Professor of Medicine
Section Chief, Gastroenterology, Hepatology and Nutrition
Inflammatory Bowel Disease Center
University of Chicago Medicine
Chicago, IL
  • Disclosures:
  • Consulting Fee: AbbVie, AbGenomics, Allergan, Biomica, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Check-Cap, Dizal Pharmaceutical, GalenPharma/Atlantica, Genentech/Roche, Gilead, GlaxoSmithKline, Glenmark, Janssen, Lilly, Mahana Therapeutics, Medtronic, Narrow River Management, Pfizer, Prometheus, Reistone, Seres Therapeutics, Shire, Takeda, Target PharmaSolutions
  • Contracted Research: AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda
  • Ownership Interest: Cornerstones Health, Inc., GoDuRun, LLC
  • Board of Trustees: American College of Gastroenterology


Corey A. Siegel, MD, MS
Professor of Medicine and of the Dartmouth Institute for Health Policy and Clinical Practice
Geisel School of Medicine at Dartmouth
Section Chief, Gastroenterology and Hepatology
Co-director, Dartmouth-Hitchcock Inflammatory Bowel Disease Center
Lebanon, NH
  • Disclosures:
  • Consulting Fee: AbbVie, Amgen, Celgene, Janssen, Lilly, Pfizer, Prometheus, Sandoz, Sebela, Takeda
  • Contracted Research: AbbVie, Janssen, Pfizer, Takeda
  • Ownership Interest: Dartmouth-Hitchcock Medical Center and Cedars-Sinai Medical Center have a patent pending for a “System and Method of Communicating Predicted Medical Outcomes”, filed 3/24/10. Dr. Corey Siegel and Dr. Lori Siegel are inventors and co-founders of MiTest Health, LLC. Patent pending for “Dietary Purgatives”, filed 7/9/2009. Dr. Corey Siegel is an inventor and co-founder of ColonaryConcepts, LLC


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosures: No relevant financial relationships to disclose
Vindico Medical Education staff report the following relationship(s):
  • No relevant financial relationships to disclose

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 29, 2020 to January 28, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, watch the videos, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate

Overview

Inflammatory bowel disease (IBD), of which Crohn’s disease and ulcerative colitis are the two main subtypes, is a chronic, relapsing condition characterized by an overly active immune response to the gut enteric flora, resulting in bowel inflammation and ulceration. IBD has a detrimental effect on quality of life for patients who suffer from this disease. Despite the increasing prevalence of IBD, gastroenterology fellows receive inadequate education regarding the diagnosis, classification, and management of these patients. This series, based on the Third Annual IBD Summit for Fellows, will feature expert faculty who will discuss optimal strategies for providing care to patients with IBD.

Target Audience

The intended audience for the activity is gastroenterology fellows and other health care professionals involved in the management of patients with inflammatory bowel disease.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Review the importance of adherence to established quality measures for IBD management for both providers and patients.
  • Evaluate the components of effective treat-to-target approach for patients with IBD.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.75 CME
Vindico
What’s New in Flu? Advances in Therapeutic Options

What’s New in Flu? Advances in Therapeutic Options

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: January 15, 2020
Expires: January 14, 2021
45 minutes to complete

Provided By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is emergency medicine physicians and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Incorporate diagnostic assays into practice that have demonstrated improved sensitivity, specificity, and convenience to improve the detection of influenza.
  • Implement effective practices and procedures that reduce the spread of influenza in the hospital setting.
  • Utilize therapeutic regimens that effectively treat influenza as well as reduce its complications.

Activity Description

Although the impact of influenza varies, it places a substantial burden on the health of children and adults in the United States each year. Emergency departments are a frequent point of entry for many influenza cases and are well-positioned to identify and manage influenza community outbreaks and epidemics. Clinical trials and observational data show that early antiviral treatment can shorten the duration of fever and illness symptoms and may reduce the risk of complications from influenza. Three classes of antiviral drugs are currently available for the prevention and treatment of influenza: neuraminidase inhibitors, adamantanes, and the polymerase inhibitor baloxavir marboxil. The faculty of this CME activity will explore existing and newer diagnostic methods for influenza as well as approved antiviral agents regarding their novel mechanisms of action, ability to reduce duration of clinical illness and complications, and cessation of viral shedding.

Agenda

Diagnosing Flu in the ED – Jason E. Bowling, MD
Case Presentation – Joseph D. Toscano, MD
Influenza Treatment – Paul G. Auwaerter, MD, MBA
Case Presentation – Joseph D. Toscano, MD
Wheel of Flu Knowledge – Frank LoVecchio, DO, MPH, FACEP

Faculty

Activity Chair:
Frank LoVecchio, DO, MPH, FACEP
Banner Good Samaritan Poison and Drug Information Center
Department of Emergency Medicine
Maricopa Integrated Health Systems
Professor, Research Scholar
University of Arizona and Creighton
College of Medicine
Phoenix, AZ
  • Disclosure: Royalty: UpToDate, Inc.


Faculty:
Paul G. Auwaerter, MD, MBA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure: Consulting Fee: DiaSorin, Shionogi
  • Ownership Interest: Johnson & Johnson


Jason E. Bowling, MD
Associate Professor
Department of Medicine, Division of Infectious Diseases
Director of Hospital Epidemiology, University Health System
UT Health San Antonio
San Antonio, TX
  • Disclosure: No relevant financial relationships to disclose.


Joseph D. Toscano, MD
Emergency Physician
Chief, Emergency Medicine
San Ramon Regional Medical Center
San Ramon, CA
  • Disclosure: No relevant financial relationships to disclose.


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
  • Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: January 15, 2020
Expires: January 14, 2021
45 minutes to complete

Provided By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is emergency medicine physicians and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Incorporate diagnostic assays into practice that have demonstrated improved sensitivity, specificity, and convenience to improve the detection of influenza.
  • Implement effective practices and procedures that reduce the spread of influenza in the hospital setting.
  • Utilize therapeutic regimens that effectively treat influenza as well as reduce its complications.

Activity Description

Although the impact of influenza varies, it places a substantial burden on the health of children and adults in the United States each year. Emergency departments are a frequent point of entry for many influenza cases and are well-positioned to identify and manage influenza community outbreaks and epidemics. Clinical trials and observational data show that early antiviral treatment can shorten the duration of fever and illness symptoms and may reduce the risk of complications from influenza. Three classes of antiviral drugs are currently available for the prevention and treatment of influenza: neuraminidase inhibitors, adamantanes, and the polymerase inhibitor baloxavir marboxil. The faculty of this CME activity will explore existing and newer diagnostic methods for influenza as well as approved antiviral agents regarding their novel mechanisms of action, ability to reduce duration of clinical illness and complications, and cessation of viral shedding.

Agenda

Diagnosing Flu in the ED – Jason E. Bowling, MD
Case Presentation – Joseph D. Toscano, MD
Influenza Treatment – Paul G. Auwaerter, MD, MBA
Case Presentation – Joseph D. Toscano, MD
Wheel of Flu Knowledge – Frank LoVecchio, DO, MPH, FACEP

Faculty

Activity Chair:
Frank LoVecchio, DO, MPH, FACEP
Banner Good Samaritan Poison and Drug Information Center
Department of Emergency Medicine
Maricopa Integrated Health Systems
Professor, Research Scholar
University of Arizona and Creighton
College of Medicine
Phoenix, AZ
  • Disclosure: Royalty: UpToDate, Inc.


Faculty:
Paul G. Auwaerter, MD, MBA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure: Consulting Fee: DiaSorin, Shionogi
  • Ownership Interest: Johnson & Johnson


Jason E. Bowling, MD
Associate Professor
Department of Medicine, Division of Infectious Diseases
Director of Hospital Epidemiology, University Health System
UT Health San Antonio
San Antonio, TX
  • Disclosure: No relevant financial relationships to disclose.


Joseph D. Toscano, MD
Emergency Physician
Chief, Emergency Medicine
San Ramon Regional Medical Center
San Ramon, CA
  • Disclosure: No relevant financial relationships to disclose.


Reviewer:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • Disclosure: No relevant financial relationships to disclose.
Vindico Medical Education Staff:
  • Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the CME posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME / CE
American Heart Association
HeartBEATS from Lifelong Learning™ Heart Failure Guidelines Series: Episode 3

HeartBEATS from Lifelong Learning™ Heart Failure Guidelines Series: Episode 3

Start

Activity Details

Free CME/CE
0.25 AMA PRA Category 1 Credits
0.25 Contact Hour(s)
Released: September 1, 2018
Expires: September 1, 2021
20 minutes to complete

Accredited By


American Heart Association

Target Audience

Physicians and nurses specific to treating patients with heart failure.

Learning Objectives

At the completion of this course, the learner will be able to:

  • List treatments of hypertension in HFrEF.
  • Describe treatment of HFpEF from hypertension and atrial fibrillation.
  • Discuss the 2017 guideline recommendations for treatment of anemia and sleep-disordered breathing.
  • Explain the role of novel pharmacological therapies in HFrEF.
  • Identify treatment of Advanced Heart Failure.

Activity Description

This series focuses on recent studies and the latest evidence for current best practices in reducing preventable hospital readmissions in heart failure. Experts address challenges, areas identified as greatest need from the Providing Healthcare Teams with Learning and Education to Impact Patient Care webinar and reinforce practice and behavior aspects that will contribute to improved patient care and outcomes.

Statement of Educational Need

With the release of new guidelines, healthcare professionals will need education and learning in order to change practice and behavior for the care and treatment of patients with or at risk of cardiovascular disease. This educational series is an important opportunity to educate healthcare professionals on evidence-based guidelines, especially those that are newly released, addressing changes, evidence, and action that can be put into practice immediately to impact patient care and outcomes.

Agenda

Dr. Butler, 9:47 minutes: Expert discussion
Dr. Chow, 10:03 minutes: Expert discussion

Presenters

Javed Butler, MD, MPH, MBA, FACC, FAHA, FESC
Co-Director of the Heart Institute
Chief of Division of Cardiology
Stony Brook University
Stony Brook, NY


Sheryl Chow, PharmD, FCCP, FAHA, FHFSA, BCPS AQ-Cardiology
Associate Professor
Pharmacy Practice and Administration
Western University of Health Sciences
Pomona, CA

Planning Committee (Content Developers)

Mark Drazner, MD – Planning Committee Chair, course author
Clinical Chief of Cardiology
Medical Director of the LVAD and Cardiac Transplantation Program
Professor of Internal Medicine
UT Southwestern

Deborah Crabbe, MD - Planning Committee, course author
Professor of Medicine
Lewis Katz School of Medicine
Temple University

Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA - Planning Committee, course author
Adjunct Assistant Clinical Professor
University of Illinois at Chicago School of Medicine

Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA - Planning Committee, course author
Associate Chief Nursing Officer
Research and Innovation
Cleveland Clinic Health System, Kaufman Center for Heart Failure

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represent the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Mark Drazner, MD – No disclosures
Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA – Employed by Roche Diagnostics Corp.
Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Novartis: Speaker bureau, consultant on research projects; Amgen: Speaker bureau
Deborah Crabbe, MD – No disclosures
Javed Butler, MD, MPH, MBA, FACC, FAHA, FESC – Amgen, Astra Zeneca, Bayer, Boelinger, Bristol Meyer Squib, Merck, Novartis: Consultant/Advisory board
Sheryl Chow, PharmD, FCCP, FAHA, FHFSA, BCPS AQ-Cardiology – Novartis: Consultant

Accreditation Statements

ORIGINAL RELEASE DATE: 09/01/2018

TERMINATION DATE: 09/01/2021

LAST REVIEW DATE: August 2018

JOINT ACCREDITATION TERM: 09/01/2018 – 09/01/2021

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 0.25 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

Participation and Successful Completion

Successful completion of this CME/CE activity includes the following:

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 75%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Novartis Pharmaceuticals Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Fred Porta
Program Manager, Lifelong Learning
AHA National Center
fred.porta@heart.org
817-412-1941

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Activity Details

Free CME/CE
0.25 AMA PRA Category 1 Credits
0.25 Contact Hour(s)
Released: September 1, 2018
Expires: September 1, 2021
20 minutes to complete

Accredited By


American Heart Association

Target Audience

Physicians and nurses specific to treating patients with heart failure.

Learning Objectives

At the completion of this course, the learner will be able to:

  • List treatments of hypertension in HFrEF.
  • Describe treatment of HFpEF from hypertension and atrial fibrillation.
  • Discuss the 2017 guideline recommendations for treatment of anemia and sleep-disordered breathing.
  • Explain the role of novel pharmacological therapies in HFrEF.
  • Identify treatment of Advanced Heart Failure.

Activity Description

This series focuses on recent studies and the latest evidence for current best practices in reducing preventable hospital readmissions in heart failure. Experts address challenges, areas identified as greatest need from the Providing Healthcare Teams with Learning and Education to Impact Patient Care webinar and reinforce practice and behavior aspects that will contribute to improved patient care and outcomes.

Statement of Educational Need

With the release of new guidelines, healthcare professionals will need education and learning in order to change practice and behavior for the care and treatment of patients with or at risk of cardiovascular disease. This educational series is an important opportunity to educate healthcare professionals on evidence-based guidelines, especially those that are newly released, addressing changes, evidence, and action that can be put into practice immediately to impact patient care and outcomes.

Agenda

Dr. Butler, 9:47 minutes: Expert discussion
Dr. Chow, 10:03 minutes: Expert discussion

Presenters

Javed Butler, MD, MPH, MBA, FACC, FAHA, FESC
Co-Director of the Heart Institute
Chief of Division of Cardiology
Stony Brook University
Stony Brook, NY


Sheryl Chow, PharmD, FCCP, FAHA, FHFSA, BCPS AQ-Cardiology
Associate Professor
Pharmacy Practice and Administration
Western University of Health Sciences
Pomona, CA

Planning Committee (Content Developers)

Mark Drazner, MD – Planning Committee Chair, course author
Clinical Chief of Cardiology
Medical Director of the LVAD and Cardiac Transplantation Program
Professor of Internal Medicine
UT Southwestern

Deborah Crabbe, MD - Planning Committee, course author
Professor of Medicine
Lewis Katz School of Medicine
Temple University

Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA - Planning Committee, course author
Adjunct Assistant Clinical Professor
University of Illinois at Chicago School of Medicine

Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA - Planning Committee, course author
Associate Chief Nursing Officer
Research and Innovation
Cleveland Clinic Health System, Kaufman Center for Heart Failure

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represent the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Mark Drazner, MD – No disclosures
Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA – Employed by Roche Diagnostics Corp.
Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Novartis: Speaker bureau, consultant on research projects; Amgen: Speaker bureau
Deborah Crabbe, MD – No disclosures
Javed Butler, MD, MPH, MBA, FACC, FAHA, FESC – Amgen, Astra Zeneca, Bayer, Boelinger, Bristol Meyer Squib, Merck, Novartis: Consultant/Advisory board
Sheryl Chow, PharmD, FCCP, FAHA, FHFSA, BCPS AQ-Cardiology – Novartis: Consultant

Accreditation Statements

ORIGINAL RELEASE DATE: 09/01/2018

TERMINATION DATE: 09/01/2021

LAST REVIEW DATE: August 2018

JOINT ACCREDITATION TERM: 09/01/2018 – 09/01/2021

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 0.25 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

Participation and Successful Completion

Successful completion of this CME/CE activity includes the following:

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 75%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Novartis Pharmaceuticals Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Fred Porta
Program Manager, Lifelong Learning
AHA National Center
fred.porta@heart.org
817-412-1941

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.25 CME / CE
American Heart Association
HeartBEATS from Lifelong Learning™ Heart Failure Guidelines Series: Episode 1

HeartBEATS from Lifelong Learning™ Heart Failure Guidelines Series: Episode 1

Start

Activity Details

Free CME/CE
0.25 AMA PRA Category 1 Credits
0.25 Contact Hour(s)
Released: September 1, 2018
Expires: September 1, 2021
19 minutes to complete

Accredited By


American Heart Association

Target Audience

Physicians and nurses specific to treating patients with heart failure.

Learning Objectives

At the completion of this course, the learner will be able to:

  • List treatments of hypertension in HFrEF.
  • Describe treatment of HFpEF from hypertension and atrial fibrillation.
  • Discuss the 2017 guideline recommendations for treatment of anemia and sleep-disordered breathing.
  • Explain the role of novel pharmacological therapies in HFrEF.
  • Identify treatment of Advanced Heart Failure.

Activity Description

This series focuses on recent studies and the latest evidence for current best practices in reducing preventable hospital readmissions in heart failure. Experts address challenges, areas identified as greatest need from the Providing Healthcare Teams with Learning and Education to Impact Patient Care webinar and reinforce practice and behavior aspects that will contribute to improved patient care and outcomes.

Statement of Educational Need

With the release of new guidelines, healthcare professionals will need education and learning in order to change practice and behavior for the care and treatment of patients with or at risk of cardiovascular disease. This educational series is an important opportunity to educate healthcare professionals on evidence-based guidelines, especially those that are newly released, addressing changes, evidence, and action that can be put into practice immediately to impact patient care and outcomes.

Agenda

Dr. Migliore, 9:47 minutes: Expert discussion
Dr. Martínez, 9:31 minutes: Expert discussion

Presenters

Ricardo Alberto Migliore, MD
Head of Diagnosis & Treatment, Cardiology Services
Hospital Interzonal de Agudos “Eva Perón”
San Martin, Buenos Aires, Argentina


Felipe Martínez, MD, FACC, FECS
Professor of Medicine
Cordoba National University
Director of Rusculleda Foundation
Cordoba, Argentina

Planning Committee (Content Developers)

Mark Drazner, MD – Planning Committee Chair, course author
Clinical Chief of Cardiology
Medical Director of the LVAD and Cardiac Transplantation Program
Professor of Internal Medicine
UT Southwestern

Deborah Crabbe, MD - Planning Committee, course author
Professor of Medicine
Lewis Katz School of Medicine
Temple University

Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA - Planning Committee, course author
Adjunct Assistant Clinical Professor
University of Illinois at Chicago School of Medicine

Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA - Planning Committee, course author
Associate Chief Nursing Officer
Research and Innovation
Cleveland Clinic Health System, Kaufman Center for Heart Failure

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represent the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Mark Drazner, MD – No disclosures
Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA – Employed by Roche Diagnostics Corp.
Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Novartis: Speaker bureau, consultant on research projects; Amgen: Speaker bureau
Deborah Crabbe, MD – No disclosures
Ricardo Alberto Migliore, MD – No disclosures
Felipe Martínez, MD, FACC, FECS – No disclosures

Accreditation Statements

ORIGINAL RELEASE DATE: 09/01/2018

TERMINATION DATE: 09/01/2021

LAST REVIEW DATE: August 2018

JOINT ACCREDITATION TERM: 09/01/2018 – 09/01/2021

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 0.25 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

Participation and Successful Completion

Successful completion of this CME/CE activity includes the following:

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 75%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Novartis Pharmaceuticals Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Fred Porta
Program Manager, Lifelong Learning
AHA National Center
fred.porta@heart.org
817-412-1941

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Activity Details

Free CME/CE
0.25 AMA PRA Category 1 Credits
0.25 Contact Hour(s)
Released: September 1, 2018
Expires: September 1, 2021
19 minutes to complete

Accredited By


American Heart Association

Target Audience

Physicians and nurses specific to treating patients with heart failure.

Learning Objectives

At the completion of this course, the learner will be able to:

  • List treatments of hypertension in HFrEF.
  • Describe treatment of HFpEF from hypertension and atrial fibrillation.
  • Discuss the 2017 guideline recommendations for treatment of anemia and sleep-disordered breathing.
  • Explain the role of novel pharmacological therapies in HFrEF.
  • Identify treatment of Advanced Heart Failure.

Activity Description

This series focuses on recent studies and the latest evidence for current best practices in reducing preventable hospital readmissions in heart failure. Experts address challenges, areas identified as greatest need from the Providing Healthcare Teams with Learning and Education to Impact Patient Care webinar and reinforce practice and behavior aspects that will contribute to improved patient care and outcomes.

Statement of Educational Need

With the release of new guidelines, healthcare professionals will need education and learning in order to change practice and behavior for the care and treatment of patients with or at risk of cardiovascular disease. This educational series is an important opportunity to educate healthcare professionals on evidence-based guidelines, especially those that are newly released, addressing changes, evidence, and action that can be put into practice immediately to impact patient care and outcomes.

Agenda

Dr. Migliore, 9:47 minutes: Expert discussion
Dr. Martínez, 9:31 minutes: Expert discussion

Presenters

Ricardo Alberto Migliore, MD
Head of Diagnosis & Treatment, Cardiology Services
Hospital Interzonal de Agudos “Eva Perón”
San Martin, Buenos Aires, Argentina


Felipe Martínez, MD, FACC, FECS
Professor of Medicine
Cordoba National University
Director of Rusculleda Foundation
Cordoba, Argentina

Planning Committee (Content Developers)

Mark Drazner, MD – Planning Committee Chair, course author
Clinical Chief of Cardiology
Medical Director of the LVAD and Cardiac Transplantation Program
Professor of Internal Medicine
UT Southwestern

Deborah Crabbe, MD - Planning Committee, course author
Professor of Medicine
Lewis Katz School of Medicine
Temple University

Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA - Planning Committee, course author
Adjunct Assistant Clinical Professor
University of Illinois at Chicago School of Medicine

Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA - Planning Committee, course author
Associate Chief Nursing Officer
Research and Innovation
Cleveland Clinic Health System, Kaufman Center for Heart Failure

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represent the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Mark Drazner, MD – No disclosures
Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA – Employed by Roche Diagnostics Corp.
Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Novartis: Speaker bureau, consultant on research projects; Amgen: Speaker bureau
Deborah Crabbe, MD – No disclosures
Ricardo Alberto Migliore, MD – No disclosures
Felipe Martínez, MD, FACC, FECS – No disclosures

Accreditation Statements

ORIGINAL RELEASE DATE: 09/01/2018

TERMINATION DATE: 09/01/2021

LAST REVIEW DATE: August 2018

JOINT ACCREDITATION TERM: 09/01/2018 – 09/01/2021

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 0.25 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

Participation and Successful Completion

Successful completion of this CME/CE activity includes the following:

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 75%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Novartis Pharmaceuticals Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Fred Porta
Program Manager, Lifelong Learning
AHA National Center
fred.porta@heart.org
817-412-1941

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

0.25 CME / CE
American Heart Association
HeartBEATS from Lifelong Learning™ Heart Failure Guidelines Series: Episode 2

HeartBEATS from Lifelong Learning™ Heart Failure Guidelines Series: Episode 2

Start

Activity Details

Free CME/CE
0.25 AMA PRA Category 1 Credits
0.25 Contact Hour(s)
Released: September 1, 2018
Expires: September 1, 2021
16 minutes to complete

Accredited By


American Heart Association

Target Audience

Physicians and nurses specific to treating patients with heart failure.

Learning Objectives

At the completion of this course, the learner will be able to:

  • List treatments of hypertension in HFrEF.
  • Describe treatment of HFpEF from hypertension and atrial fibrillation.
  • Discuss the 2017 guideline recommendations for treatment of anemia and sleep-disordered breathing.
  • Explain the role of novel pharmacological therapies in HFrEF.
  • Identify treatment of Advanced Heart Failure.

Activity Description

This series focuses on recent studies and the latest evidence for current best practices in reducing preventable hospital readmissions in heart failure. Experts address challenges, areas identified as greatest need from the Providing Healthcare Teams with Learning and Education to Impact Patient Care webinar and reinforce practice and behavior aspects that will contribute to improved patient care and outcomes.

Statement of Educational Need

With the release of new guidelines, healthcare professionals will need education and learning in order to change practice and behavior for the care and treatment of patients with or at risk of cardiovascular disease. This educational series is an important opportunity to educate healthcare professionals on evidence-based guidelines, especially those that are newly released, addressing changes, evidence, and action that can be put into practice immediately to impact patient care and outcomes.

Agenda

Dr. Fonarow, 13:23 minutes: Expert discussion
Dr. Ventura, 2:50 minutes: Expert discussion

Presenters

Gregg Fonarow, MD, FACC, FAHA, FHFSA
Co-Chief of Cardiology
Director, Ahmanson-UCLA Preventative Cardiomyopathy Center
Ronald Reagan UCLA Medical Center
Los Angeles, CA


Hector Ventura, MD
Section Head, Cardiomyopathy and Heart Transplantation
Ochsner Medical Center
New Orleans, LA

Planning Committee (Content Developers)

Mark Drazner, MD – Planning Committee Chair, course author
Clinical Chief of Cardiology
Medical Director of the LVAD and Cardiac Transplantation Program
Professor of Internal Medicine
UT Southwestern

Deborah Crabbe, MD - Planning Committee, course author
Professor of Medicine
Lewis Katz School of Medicine
Temple University

Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA - Planning Committee, course author
Adjunct Assistant Clinical Professor
University of Illinois at Chicago School of Medicine

Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA - Planning Committee, course author
Associate Chief Nursing Officer
Research and Innovation
Cleveland Clinic Health System, Kaufman Center for Heart Failure

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represent the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Mark Drazner, MD – No disclosures
Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA – Employed by Roche Diagnostics Corp.
Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Novartis: Speaker bureau, consultant on research projects; Amgen: Speaker bureau
Deborah Crabbe, MD – No disclosures
Greg Fonarow, MD, FACC, FAHA, FHFSA – Novartis, Medtronic, Janssen, Bayer, ST. Jude, Amgen: Consultant/Advisory Board
Hector Ventura, MD – No disclosures

Accreditation Statements

ORIGINAL RELEASE DATE: 09/01/2018

TERMINATION DATE: 09/01/2021

LAST REVIEW DATE: August 2018

JOINT ACCREDITATION TERM: 09/01/2018 – 09/01/2021

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 0.25 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

Participation and Successful Completion

Successful completion of this CME/CE activity includes the following:

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 75%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Novartis Pharmaceuticals Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Fred Porta
Program Manager, Lifelong Learning
AHA National Center
fred.porta@heart.org
817-412-1941

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Activity Details

Free CME/CE
0.25 AMA PRA Category 1 Credits
0.25 Contact Hour(s)
Released: September 1, 2018
Expires: September 1, 2021
16 minutes to complete

Accredited By


American Heart Association

Target Audience

Physicians and nurses specific to treating patients with heart failure.

Learning Objectives

At the completion of this course, the learner will be able to:

  • List treatments of hypertension in HFrEF.
  • Describe treatment of HFpEF from hypertension and atrial fibrillation.
  • Discuss the 2017 guideline recommendations for treatment of anemia and sleep-disordered breathing.
  • Explain the role of novel pharmacological therapies in HFrEF.
  • Identify treatment of Advanced Heart Failure.

Activity Description

This series focuses on recent studies and the latest evidence for current best practices in reducing preventable hospital readmissions in heart failure. Experts address challenges, areas identified as greatest need from the Providing Healthcare Teams with Learning and Education to Impact Patient Care webinar and reinforce practice and behavior aspects that will contribute to improved patient care and outcomes.

Statement of Educational Need

With the release of new guidelines, healthcare professionals will need education and learning in order to change practice and behavior for the care and treatment of patients with or at risk of cardiovascular disease. This educational series is an important opportunity to educate healthcare professionals on evidence-based guidelines, especially those that are newly released, addressing changes, evidence, and action that can be put into practice immediately to impact patient care and outcomes.

Agenda

Dr. Fonarow, 13:23 minutes: Expert discussion
Dr. Ventura, 2:50 minutes: Expert discussion

Presenters

Gregg Fonarow, MD, FACC, FAHA, FHFSA
Co-Chief of Cardiology
Director, Ahmanson-UCLA Preventative Cardiomyopathy Center
Ronald Reagan UCLA Medical Center
Los Angeles, CA


Hector Ventura, MD
Section Head, Cardiomyopathy and Heart Transplantation
Ochsner Medical Center
New Orleans, LA

Planning Committee (Content Developers)

Mark Drazner, MD – Planning Committee Chair, course author
Clinical Chief of Cardiology
Medical Director of the LVAD and Cardiac Transplantation Program
Professor of Internal Medicine
UT Southwestern

Deborah Crabbe, MD - Planning Committee, course author
Professor of Medicine
Lewis Katz School of Medicine
Temple University

Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA - Planning Committee, course author
Adjunct Assistant Clinical Professor
University of Illinois at Chicago School of Medicine

Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA - Planning Committee, course author
Associate Chief Nursing Officer
Research and Innovation
Cleveland Clinic Health System, Kaufman Center for Heart Failure

Disclosures

All persons who develop and/or control educational content in CME/CE activities provided by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.

The disclosures listed below represent the relationships of this educational activity’s faculty members that may be perceived as actual or reasonable perceived conflicts of interest as reported on the Disclosure Questionnaire which all AHA volunteers are required to complete and submit. The focus is on relevant financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content.

Mark Drazner, MD – No disclosures
Robin Trupp, PhD, ACNP-BC, APRN, CHFN FAHA – Employed by Roche Diagnostics Corp.
Nancy Albert, PhD, CCNS, CHFN, CCRN, FAHA – Novartis: Speaker bureau, consultant on research projects; Amgen: Speaker bureau
Deborah Crabbe, MD – No disclosures
Greg Fonarow, MD, FACC, FAHA, FHFSA – Novartis, Medtronic, Janssen, Bayer, ST. Jude, Amgen: Consultant/Advisory Board
Hector Ventura, MD – No disclosures

Accreditation Statements

ORIGINAL RELEASE DATE: 09/01/2018

TERMINATION DATE: 09/01/2021

LAST REVIEW DATE: August 2018

JOINT ACCREDITATION TERM: 09/01/2018 – 09/01/2021

The American Heart Association is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

AMA Credit Designation Statement - Physicians
The American Heart Association designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA Credit Acceptance Statement – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.25 hours of Category 1 credit for completing this program.

AANP Credit Acceptance Statement – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. **AMA Credit must be claimed within 6 months of attendance. Credit will no longer be available to claim after the 6 months claiming period.

ANCC Credit Designation Statement - Nurses
The maximum number of hours awarded for this CE activity is 0.25 contact hours. **ANCC Credit must be claimed within 6 months of attendance. CME/CE will no longer be available to claim after the 6 months claiming period.

Participation and Successful Completion

Successful completion of this CME/CE activity includes the following:

  1. Register and view the course online.
  2. View the content in its entirety.
  3. Complete a post-test with a minimum score of 75%.
  4. Complete a survey of your learning experience.
  5. Claim your CME/CE Certificate.

Statement of Commercial Support

This activity is supported by independent medical educational grants from Novartis Pharmaceuticals Corporation.

Disclaimer Statement/Disclosure of Unlabeled Use

When an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, the faculty must disclose that the product is not labeled for the use under discussion or that the product is still investigational.

Contact Information for Questions about the Activity

Fred Porta
Program Manager, Lifelong Learning
AHA National Center
fred.porta@heart.org
817-412-1941

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Pages